Literature DB >> 29700173

The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic/myeloproliferative neoplasms.

Manja Meggendorfer1, Sabine Jeromin2, Claudia Haferlach2, Wolfgang Kern2, Torsten Haferlach2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29700173      PMCID： PMC5927999          DOI： 10.3324/haematol.2017.183160

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Molecular basis of myelodysplastic/myeloproliferative neoplasms.

Authors:  Andreas Reiter; Rosangela Invernizzi; Nicholas C P Cross; Mario Cazzola
Journal:  Haematologica       Date:  2009-12       Impact factor: 9.941

2.  Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations.

Authors:  Sabine Jeromin; Torsten Haferlach; Sandra Weissmann; Manja Meggendorfer; Christiane Eder; Niroshan Nadarajah; Tamara Alpermann; Alexander Kohlmann; Wolfgang Kern; Claudia Haferlach; Susanne Schnittger
Journal:  Haematologica       Date:  2014-12-19       Impact factor: 9.941

3.  Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia.

Authors:  Manja Meggendorfer; Torsten Haferlach; Tamara Alpermann; Sabine Jeromin; Claudia Haferlach; Wolfgang Kern; Susanne Schnittger
Journal:  Haematologica       Date:  2014-09-19       Impact factor: 9.941

4.  Frequent pathway mutations of splicing machinery in myelodysplasia.

Authors:  Kenichi Yoshida; Masashi Sanada; Yuichi Shiraishi; Daniel Nowak; Yasunobu Nagata; Ryo Yamamoto; Yusuke Sato; Aiko Sato-Otsubo; Ayana Kon; Masao Nagasaki; George Chalkidis; Yutaka Suzuki; Masashi Shiosaka; Ryoichiro Kawahata; Tomoyuki Yamaguchi; Makoto Otsu; Naoshi Obara; Mamiko Sakata-Yanagimoto; Ken Ishiyama; Hiraku Mori; Florian Nolte; Wolf-Karsten Hofmann; Shuichi Miyawaki; Sumio Sugano; Claudia Haferlach; H Phillip Koeffler; Lee-Yung Shih; Torsten Haferlach; Shigeru Chiba; Hiromitsu Nakauchi; Satoru Miyano; Seishi Ogawa
Journal:  Nature       Date:  2011-09-11       Impact factor: 49.962

5.  Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.

Authors:  Rocco Piazza; Simona Valletta; Nils Winkelmann; Sara Redaelli; Roberta Spinelli; Alessandra Pirola; Laura Antolini; Luca Mologni; Carla Donadoni; Elli Papaemmanuil; Susanne Schnittger; Dong-Wook Kim; Jacqueline Boultwood; Fabio Rossi; Giuseppe Gaipa; Greta P De Martini; Paola Francia di Celle; Hyun Gyung Jang; Valeria Fantin; Graham R Bignell; Vera Magistroni; Torsten Haferlach; Enrico Maria Pogliani; Peter J Campbell; Andrew J Chase; William J Tapper; Nicholas C P Cross; Carlo Gambacorti-Passerini
Journal:  Nat Genet       Date:  2012-12-09       Impact factor: 38.330

Review 6.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

7.  Prognostic score including gene mutations in chronic myelomonocytic leukemia.

Authors:  Raphaël Itzykson; Olivier Kosmider; Aline Renneville; Véronique Gelsi-Boyer; Manja Meggendorfer; Margot Morabito; Céline Berthon; Lionel Adès; Pierre Fenaux; Odile Beyne-Rauzy; Norbert Vey; Thorsten Braun; Torsten Haferlach; François Dreyfus; Nicholas C P Cross; Claude Preudhomme; Olivier A Bernard; Michaela Fontenay; William Vainchenker; Susanne Schnittger; Daniel Birnbaum; Nathalie Droin; Eric Solary
Journal:  J Clin Oncol       Date:  2013-05-20       Impact factor: 44.544

8.  Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.

Authors:  Sa A Wang; Robert P Hasserjian; Patricia S Fox; Heesun J Rogers; Julia T Geyer; Devon Chabot-Richards; Elizabeth Weinzierl; Joseph Hatem; Jesse Jaso; Rashmi Kanagal-Shamanna; Francesco C Stingo; Keyur P Patel; Meenakshi Mehrotra; Carlos Bueso-Ramos; Ken H Young; Courtney D Dinardo; Srdan Verstovsek; Ramon V Tiu; Adam Bagg; Eric D Hsi; Daniel A Arber; Kathryn Foucar; Raja Luthra; Attilio Orazi
Journal:  Blood       Date:  2014-03-13       Impact factor: 22.113

Review 9.  The genetic basis of myelodysplasia and its clinical relevance.

Authors:  Mario Cazzola; Matteo G Della Porta; Luca Malcovati
Journal:  Blood       Date:  2013-10-17       Impact factor: 22.113

10.  Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Luca Malcovati; Sudhir Tauro; Gunes Gundem; Peter Van Loo; Chris J Yoon; Peter Ellis; David C Wedge; Andrea Pellagatti; Adam Shlien; Michael John Groves; Simon A Forbes; Keiran Raine; Jon Hinton; Laura J Mudie; Stuart McLaren; Claire Hardy; Calli Latimer; Matteo G Della Porta; Sarah O'Meara; Ilaria Ambaglio; Anna Galli; Adam P Butler; Gunilla Walldin; Jon W Teague; Lynn Quek; Alex Sternberg; Carlo Gambacorti-Passerini; Nicholas C P Cross; Anthony R Green; Jacqueline Boultwood; Paresh Vyas; Eva Hellstrom-Lindberg; David Bowen; Mario Cazzola; Michael R Stratton; Peter J Campbell
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113
View more
  11 in total

1.  Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients.

Authors:  Abhishek A Mangaonkar; David M Swoboda; Giacomo Coltro; Terra L Lasho; Paul J Novotny; Prateek Pophali; Ryan M Carr; Moritz Binder; Christy M Finke; Naseema Gangat; Aref Al-Kali; Kebede H Begna; Kaaren K Reichard; Rhett P Ketterling; Najla H Al Ali; Pardis Vafaii; Ling Zhang; Eric Padron; Chetasi Talati; Mrinal M Patnaik
Journal:  Leukemia       Date:  2019-09-11       Impact factor: 11.528

Review 2.  Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.

Authors:  Mrinal M Patnaik; Terra L Lasho
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 3.  Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms.

Authors:  Michael J Hochman; Bipin N Savani; Tania Jain
Journal:  EJHaem       Date:  2021-07-19

4.  Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019.

Authors:  Konnie Hebeda; Ludmila Boudova; Christine Beham-Schmid; Attilio Orazi; Hans-Michael Kvasnicka; Umberto Gianelli; Alexandar Tzankov
Journal:  Ann Hematol       Date:  2020-10-31       Impact factor: 3.673

Review 5.  Clinical and Molecular Approach to Adult-Onset, Neoplastic Monocytosis.

Authors:  Rory M Shallis; Alexa J Siddon; Amer M Zeidan
Journal:  Curr Hematol Malig Rep       Date:  2021-04-22       Impact factor: 3.952

6.  Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.

Authors:  Theodoros Karantanos; Lukasz P Gondek; Ravi Varadhan; Alison R Moliterno; Amy E DeZern; Richard J Jones; Tania Jain
Journal:  Br J Haematol       Date:  2021-05-24       Impact factor: 8.615

7.  Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet.

Authors:  Raphael Itzykson; Pierre Fenaux; David Bowen; Nicholas C P Cross; Jorge Cortes; Theo De Witte; Ulrich Germing; Francesco Onida; Eric Padron; Uwe Platzbecker; Valeria Santini; Guillermo F Sanz; Eric Solary; Arjan Van de Loosdrecht; Luca Malcovati
Journal:  Hemasphere       Date:  2018-11-29

8.  A Phase I trial of talazoparib in patients with advanced hematologic malignancies.

Authors:  Ajay K Gopal; Rakesh Popat; Ryan J Mattison; Tobias Menne; Adrian Bloor; Terry Gaymes; Asim Khwaja; Mark Juckett; Ying Chen; Matthew J Cotter; Ghulam J Mufti
Journal:  Int J Hematol Oncol       Date:  2021-10-22

9.  Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group.

Authors:  Rashmi Kanagal-Shamanna; Attilio Orazi; Robert P Hasserjian; Daniel A Arber; Kaaren Reichard; Eric D Hsi; Adam Bagg; Heesun Joyce Rogers; Julia Geyer; Faezeh Darbaniyan; Kim-Anh Do; Kyle M Devins; Olga Pozdnyakova; Tracy I George; Paola Dal Cin; Patricia T Greipp; Mark J Routbort; Keyur Patel; Guillermo Garcia-Manero; Srdan Verstovsek; L Jeffrey Medeiros; Sa A Wang; Carlos Bueso-Ramos
Journal:  Mod Pathol       Date:  2021-11-13       Impact factor: 7.842

Review 10.  SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms.

Authors:  Katherine Linder; Chaitanya Iragavarapu; Amandeep Aujla; Michael Karass; Delong Liu
Journal:  Biomark Res       Date:  2018-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.